Fisher & Paykel HealthcareASX:FPH +3.44%86 ROA % is 18.03% as of Mar. 2026, which is 2% below its 10-year median of 18.39. GuruFocus rates ASX:FPH with a GF Score™ of 86/100 and a GF Value™ of A$36.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 95.92% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Fisher & Paykel Healthcare's annualizedNet Income for the quarter that ended in Mar. 2026 was A$426 Mil.
Fisher & Paykel Healthcare's average Total Assets over the quarter that ended in Mar. 2026 was A$2,362 Mil. Therefore, Fisher & Paykel Healthcare's annualized ROA % for the quarter that ended in Mar. 2026 was 18.03%.
The historical rank and industry rank for Fisher & Paykel Healthcare's ROA % or its related term are showing as below:
ASX:FPH'
s ROA % Range Over the Past 10 Years
Min: 5.91 Med: 18.39 Max: 29.87
Current: 17.49
During the past 13 years, Fisher & Paykel Healthcare's highest ROA % was 29.87%. The lowest was 5.91%. And the median was 18.39%.
ASX:FPH's ROA % is ranked better than 95.92% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs ASX:FPH: 17.49
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's ROA % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Fisher & Paykel Healthcare (ASX:FPH) has a ROA % of 18.03% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 18.39. Over the past decade, Fisher & Paykel Healthcare's ROA % has ranged from 5.91 to 29.87. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #35 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 4.1%.
Is Fisher & Paykel Healthcare's ROA % too high?
Fisher & Paykel Healthcare's current ROA % of 18.03% is near median its 10-year median of 18.39. Over the past 10 years, this metric has ranged from a low of 5.91 to a high of 29.87. The Medical Devices & Instruments industry median ROA % is 0.59. Fisher & Paykel Healthcare's value of 18.03% is 2955.9% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #35 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #35 out of 857 companies for ROA %. This places Fisher & Paykel Healthcare in the top 4% of its industry — outperforming the majority of peers. The industry median ROA % is 0.59. Fisher & Paykel Healthcare's value of 18.03% is 2955.9% above this benchmark. Historically, Fisher & Paykel Healthcare's own ROA % has ranged from 5.91 to 29.87 over the past decade. While the company's 10-year median is 18.39 vs. the industry median of 0.59, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current ROA % of 18.03% is 2955.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current ROA % is 18.03%, which is near median its own 10-year median of 18.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.31, compared to a current price of A$31.53 — trading 13.2% below its estimated fair value. The current ROA % is 18.03%, which is near median its 10-year median of 18.39 and 2955.9% above the Medical Devices & Instruments industry median of 0.59. Fisher & Paykel Healthcare's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current ROA % is 18.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$31.53 is trading 13.2% below its estimated GF Value™ of A$36.31.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
ROA %: 18.03% (near median its 10-year median of 18.39)
GF Value™: A$36.31 vs. price of A$31.53 (13.2% below fair value)
Industry Position: 2955.9% above the Medical Devices & Instruments median (#35 of 857)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
86GF Score
Get the complete analysis for ASX:FPH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
